Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature
We are currently in a global pandemic caused by the coronavirus 2019 or COVID-19, presenting different challenges for the health system due to the fact that there is still no vaccine or a treatment that has proven its effectiveness in its entirety, being the management current preventive and support...
| Authors: | , , |
|---|---|
| Format: | article |
| Status: | Published version |
| Publication Date: | 2021 |
| Country: | Perú |
| Institution: | Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| Repository: | Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| Language: | Spanish |
| OAI Identifier: | oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/821 |
| Online Access: | https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/821 |
| Access Level: | Open access |
| Keyword: | COVID–19 Hidroxicloroquina Tocilizumab Anakinra Baricitinib Agentes antirreumáticos COVID-19 hydroxychloroquine tocilizumab anakinra baricitinib antirheumatic agents |
| Summary: | We are currently in a global pandemic caused by the coronavirus 2019 or COVID-19, presenting different challenges for the health system due to the fact that there is still no vaccine or a treatment that has proven its effectiveness in its entirety, being the management current preventive and supportive. Therefore, this review will study the most prominent antirheumatic drugs that have a probable pharmacological effect, such as hydroxychloroquine, tocilizumab, anakinra and baricitinib, against COVID-19. It is expected that they will provide support for future treatments. and research on the disease. |
|---|